Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Director | June 04, 2026 | June 08, 2026 |
| Entasis Therapeutics Holdings Inc.ETTX · Entity 16036 | 10% owner | September 28, 2018 | October 02, 2018 |
| Galera Therapeutics, Inc.GRTX · Entity 15899 | 10% owner | November 12, 2019 | November 12, 2019 |
| Iterum Therapeutics plcITRM · Entity 72802 | 10% owner | May 30, 2018 | May 30, 2018 |
| Merus N.V.MRUS · Entity 70740 | Director | December 12, 2025 | December 13, 2025 |
| Principia Biopharma Inc.PRNB · Entity 146423 | 10% owner | September 18, 2018 | September 20, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 726,403 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Exercise / conversion · Acquired 11,580 · Balance 726,403 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.71 · Expires 2036-06-03 | Direct | 42,350 |
Reported balance
After 2026-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-04 · Grant · Acquired 42,350 · Balance 42,350 F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,987 |
Reported balance
After 2026-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-04 · Grant · Acquired 10,987 · Balance 10,987 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-05 · Exercise / conversion · Disposed 11,580 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5: The shares underlying these restricted stock units vested on June 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.
F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.
F5: The shares underlying these restricted stock units vested on June 5, 2026.
Entasis Therapeutics Holdings Inc.
Report date September 28, 2018 · Filed October 02, 2018
Jointly reported with Sofinnova Venture Partners IX, L.P., Sofinnova Management IX, L.L.C., HEALY JAMES, POWELL MICHAEL
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 359,267 |
Reported balance
After 2018-09-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-09-28 · Conversion · Acquired 359,267 · Balance 359,267 F1: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 842,454 |
Reported balance
After 2018-09-28 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-09-28 · Conversion · Acquired 458,425 · Balance 842,454 F1: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3: This number includes an aggregate of 24,762 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018. F2: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 1,180,178 |
Reported balance
After 2018-09-28 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-09-28 · Purchase · Acquired 337,724 · Balance 1,180,178 F2: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein. |
| Series B-1 Tranche A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-09-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-09-28 · Conversion · Disposed 7,446,904 · Balance 0 F1: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein. |
| Series B-1 Tranche B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-09-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-09-28 · Conversion · Disposed 9,502,249 · Balance 0 F1: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
F2: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.
F3: This number includes an aggregate of 24,762 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.
Galera Therapeutics, Inc.
Report date November 12, 2019 · Filed November 12, 2019
Jointly reported with Sofinnova Venture Partners IX, L.P., Sofinnova Management IX, L.L.C., POWELL MICHAEL, HEALY JAMES
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,083,712 |
Last balance in matching sequence
After 2019-11-12 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2019-11-12 · Conversion · Acquired 2,333,712 · Balance 2,333,712 F1: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. F2: The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein. Row 2 · 2019-11-12 · Purchase · Acquired 750,000 · Balance 3,083,712 F2: The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein. |
| Series B-2 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-11-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-12 · Conversion · Disposed 9,090,909 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. F2: The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-11-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-12 · Conversion · Disposed 2,709,659 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. F2: The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.
F2: The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein.
Iterum Therapeutics plc
Report date May 30, 2018 · Filed May 30, 2018
Jointly reported with Sofinnova Venture Partners IX, L.P., POWELL MICHAEL, Sofinnova Management IX, L.L.C.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,726,514 |
Last balance in matching sequence
After 2018-05-30 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2018-05-30 · Conversion · Acquired 721,408 · Balance 721,408 F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F2: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any. Row 2 · 2018-05-30 · Conversion · Acquired 275,446 · Balance 996,854 F3: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F2: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any. Row 3 · 2018-05-30 · Conversion · Acquired 229,660 · Balance 1,226,514 F4: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F2: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any. Row 4 · 2018-05-30 · Purchase · Acquired 500,000 · Balance 1,726,514 F2: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any. |
| Series A Preferred SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-30 · Conversion · Disposed 721,408 · Balance 0 F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F5: Not applicable. F2: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any. |
| Series B-1 Preferred SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-30 · Conversion · Disposed 275,446 · Balance 0 F3: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F5: Not applicable. F2: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any. |
| Series B-2 Preferred SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-30 · Conversion · Disposed 229,660 · Balance 0 F4: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F5: Not applicable. F2: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
F2: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any.
F3: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
F4: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
F5: Not applicable.
Merus N.V.
Report date December 12, 2025 · Filed December 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.60 · Expires 2035-05-22 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-12 · Disposition to issuer · Disposed 13,193 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.73 · Expires 2034-05-07 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-12 · Disposition to issuer · Disposed 8,844 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.29 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-12 · Disposition to issuer · Disposed 14,414 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.56 · Expires 2032-05-31 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-12 · Disposition to issuer · Disposed 16,604 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.15 · Expires 2031-05-28 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-12 · Disposition to issuer · Disposed 6,120 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.09 · Expires 2030-06-30 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-12-12 · Disposition to issuer · Disposed 8,631 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.04 · Expires 2026-05-18 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-12-12 · Disposition to issuer · Disposed 17,000 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.12 · Expires 2027-05-24 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-12-12 · Disposition to issuer · Disposed 5,650 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.30 · Expires 2028-07-20 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-12-12 · Disposition to issuer · Disposed 4,983 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.35 · Expires 2029-06-12 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-12-12 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.
F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Principia Biopharma Inc.
Report date September 18, 2018 · Filed September 20, 2018
Jointly reported with Sofinnova Venture Partners VIII, L.P., Sofinnova Management VIII, L.L.C., HEALY JAMES, POWELL MICHAEL
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,038,208 |
Last balance in matching sequence
After 2018-09-18 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2018-09-18 · Conversion · Acquired 625,482 · Balance 625,482 F1: Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock. F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein. Row 2 · 2018-09-18 · Conversion · Acquired 521,235 · Balance 1,146,717 F3: Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock. F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein. Row 3 · 2018-09-18 · Conversion · Acquired 453,954 · Balance 1,600,671 F4: Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock. F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein. Row 4 · 2018-09-18 · Conversion · Acquired 167,537 · Balance 1,768,208 F5: Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock. F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein. Row 5 · 2018-09-18 · Purchase · Acquired 270,000 · Balance 2,038,208 F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-09-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-09-18 · Conversion · Disposed 625,482 · Balance 0 F1: Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock. F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein. |
| Series B-2 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-09-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-09-18 · Conversion · Disposed 521,235 · Balance 0 F3: Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock. F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein. |
| Series B-3 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-09-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-09-18 · Conversion · Disposed 453,954 · Balance 0 F4: Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock. F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-09-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-09-18 · Conversion · Disposed 167,537 · Balance 0 F5: Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock. F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Expires 2022-12-29 | Direct | 20,938 |
Reported balance
Holding disclosure · report date 2018-09-18 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 20,938 F6: This warrant has converted from a warrant to purchase Series B-3 Convertible Preferred Stock into a warrant to purchase Common Stock. F7: This warrant is exercisable at any time. F4: Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock. F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.
F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.
F3: Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.
F4: Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.
F5: Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.
F6: This warrant has converted from a warrant to purchase Series B-3 Convertible Preferred Stock into a warrant to purchase Common Stock.
F7: This warrant is exercisable at any time.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MARINUS PHARMACEUTICALS, INC.
Report date October 20, 2016 · Filed October 24, 2016
Jointly reported with SOFINNOVA VENTURE PARTNERS VI L P, Sofinnova Venture Partners VI GmbH & Co. KG, Sofinnova Venture Affiliates VI LP, Sofinnova Management VI, L.L.C., Buatois Eric, HEALY JAMES, Azan Alain, POWELL MICHAEL
Section 16 reporting ended · disclosed 2016-10-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,134,851 |
Reported balance
After 2016-10-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2016-10-20 · Sale · Disposed 724,788 · Balance 1,134,851 F1: Shares are held by Sofinnova Venture Partners VI, L.P. ("SVP VI"). Sofinnova Management VI, L.L.C. ("SM VI") is the general partner of SVP VI and James I. Healy ("Healy"), Michael F. Powell ("Powell"), Alain L. Azan ("Azan") and Eric P. Buatois ("Buatois"), the managing members of SM VI, and Anand Mehra ("Mehra"), a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 224,845 |
Reported balance
After 2016-10-20 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2016-10-20 · Sale · Disposed 13,367 · Balance 224,845 F2: Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG ("SVP KG"). SM VI is the managing limited partner of SVP KG, and Healy, Powell, Azan and Buatois, the managing members of SM VI, and Mehra, a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 15,470 |
Reported balance
After 2016-10-20 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2016-10-20 · Sale · Disposed 12,528 · Balance 15,470 F3: Shares are held by Sofinnova Venture Affiliates VI, L.P. ("SVA VI"). SM VI is the general partner of SVA VI, and Healy, Powell, Azan and Buatois, the managing members of SM VI, and Mehra, a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares are held by Sofinnova Venture Partners VI, L.P. ("SVP VI"). Sofinnova Management VI, L.L.C. ("SM VI") is the general partner of SVP VI and James I. Healy ("Healy"), Michael F. Powell ("Powell"), Alain L. Azan ("Azan") and Eric P. Buatois ("Buatois"), the managing members of SM VI, and Anand Mehra ("Mehra"), a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities.
F2: Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG ("SVP KG"). SM VI is the managing limited partner of SVP KG, and Healy, Powell, Azan and Buatois, the managing members of SM VI, and Mehra, a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities.
F3: Shares are held by Sofinnova Venture Affiliates VI, L.P. ("SVA VI"). SM VI is the general partner of SVA VI, and Healy, Powell, Azan and Buatois, the managing members of SM VI, and Mehra, a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities.
NextCure, Inc.
Report date November 15, 2019 · Filed November 19, 2019
Jointly reported with Sofinnova Venture Partners IX, L.P., Sofinnova Management IX, L.L.C., HEALY JAMES, POWELL MICHAEL
Section 16 reporting ended · disclosed 2019-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,671,856 |
Reported balance
After 2019-11-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-11-15 · Purchase · Acquired 150,000 · Balance 2,671,856 F1: The shares are held directly by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held directly by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.
Spark Therapeutics, Inc.
Report date December 17, 2019 · Filed December 17, 2019
Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 1
1 source rowRow 1 · 2019-12-17 · Other · Disposed 40,203 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2019-12-17 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-12-17 · Other · Disposed 481,270 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. F3: The securities are owned directly by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII"), the general partner of SVP VIII, and Anand Mehra, a director of the Issuer, James I. Healy, and Michael Powell, the managing members of SM VIII, may be deemed to have shared voting and dispositive power over the shares owned by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares owned by SVP VIII except to the extent of any pecuniary interest therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.53 · Expires 2028-05-29 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.93 · Expires 2027-05-30 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.22 · Expires 2026-05-31 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-17 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
F3: The securities are owned directly by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII"), the general partner of SVP VIII, and Anand Mehra, a director of the Issuer, James I. Healy, and Michael Powell, the managing members of SM VIII, may be deemed to have shared voting and dispositive power over the shares owned by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares owned by SVP VIII except to the extent of any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 11,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001590102-26-000002 · form4-06082026_040605.xml · derivative · entry 4 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 5, 2026. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 5, 2026. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 11,580 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001590102-26-000002 · form4-06082026_040605.xml · nonDerivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 726,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 10,987 | $0.00 | $0.00 |
DisclosureSEC source: 0001590102-26-000002 · form4-06082026_040605.xml · derivative · entry 3 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,987 Underlying: Common Stock · 10,987 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (Right to Buy) · Derivative | 42,350 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001590102-26-000002 · form4-06082026_040605.xml · derivative · entry 2 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,350 Underlying: Common Stock · 42,350 shares Expires 2036-06-03 F2 · derivative.exercise_date: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:05 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $13.35 | $0.00 |
DisclosureSEC source: 0001193125-25-317964 · ownership.xml · derivative · entry 10 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,500 shares Expires 2029-06-12 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:05 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 4,983 | $0.00 Strike: $23.30 | $0.00 |
DisclosureSEC source: 0001193125-25-317964 · ownership.xml · derivative · entry 9 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,983 shares Expires 2028-07-20 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:05 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 5,650 | $0.00 Strike: $19.12 | $0.00 |
DisclosureSEC source: 0001193125-25-317964 · ownership.xml · derivative · entry 8 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,650 shares Expires 2027-05-24 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:05 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $10.04 | $0.00 |
DisclosureSEC source: 0001193125-25-317964 · ownership.xml · derivative · entry 7 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 17,000 shares Expires 2026-05-18 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:05 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 8,631 | $0.00 Strike: $16.09 | $0.00 |
DisclosureSEC source: 0001193125-25-317964 · ownership.xml · derivative · entry 6 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,631 shares Expires 2030-06-30 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:05 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 6,120 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001193125-25-317964 · ownership.xml · derivative · entry 5 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,120 shares Expires 2031-05-28 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:05 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 16,604 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001193125-25-317964 · ownership.xml · derivative · entry 4 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 16,604 shares Expires 2032-05-31 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:05 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 14,414 | $0.00 Strike: $23.29 | $0.00 |
DisclosureSEC source: 0001193125-25-317964 · ownership.xml · derivative · entry 3 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 14,414 shares Expires 2033-06-08 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:05 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 8,844 | $0.00 Strike: $48.73 | $0.00 |
DisclosureSEC source: 0001193125-25-317964 · ownership.xml · derivative · entry 2 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,844 shares Expires 2034-05-07 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:05 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 13,193 | $0.00 Strike: $41.60 | $0.00 |
DisclosureSEC source: 0001193125-25-317964 · ownership.xml · derivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 13,193 shares Expires 2035-05-22 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 4,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-016250 · form4-06092025_040608.xml · derivative · entry 4 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,793 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 6, 2025. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 6, 2025. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 4,793 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-016250 · form4-06092025_040608.xml · nonDerivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 714,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 11,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-016250 · form4-06092025_040608.xml · derivative · entry 3 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,580 Underlying: Common Stock · 11,580 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (Right to Buy) · Derivative | 42,350 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001415889-25-016250 · form4-06092025_040608.xml · derivative · entry 2 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,350 Underlying: Common Stock · 42,350 shares Expires 2035-06-04 F2 · derivative.exercise_date: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 5, 2025, subject to the Reporting Person's Continuous Service (as defined in the Plan) through each such vesting date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document |
| May 22, 2025 Filed May 27, 2025 12:00 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare Option (right to buy) · Derivative | 13,193 | $0.00 Strike: $41.60 | $0.00 |
DisclosureSEC source: 0000950170-25-077383 · ownership.xml · derivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,193 Underlying: Common Shares · 13,193 shares Expires 2035-05-22 F1 · derivative.exercise_date: Options vest over a one-year period commencing on May 22, 2025 in 12 equal monthly installments. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 21:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 666,666 | $2.25 | $1,499,998.50 |
DisclosureSEC source: 0001415889-24-027348 · form4-11202024_041101.xml · nonDerivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 710,030 F1 · shares: Represents shares of Common Stock of the Issuer acquired from the Issuer pursuant to Rule 16b-3(d). Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 4,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016192 · form4-06102024_040602.xml · derivative · entry 2 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,793 Underlying: Common Stock · 4,793 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date. F2 · balance_after: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (Right to Buy) · Derivative | 15,750 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001415889-24-016192 · form4-06102024_040602.xml · derivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 6, 2024, subject to Reporting Person's continuous service through each such date. F2 · balance_after: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 4,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015362 · form4-06042024_040606.xml · derivative · entry 2 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 1, 2024. F2 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 1, 2024. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 4,660 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-015362 · form4-06042024_040606.xml · nonDerivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| May 07, 2024 Filed May 9, 2024 20:30 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare Option (right to buy) · Derivative | 8,844 | $0.00 Strike: $48.73 | $0.00 |
DisclosureSEC source: 0000950170-24-057084 · ownership.xml · derivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,844 Underlying: Common Shares · 8,844 shares Expires 2034-05-07 F1 · derivative.exercise_date: Options vest over a one-year period commencing May 7, 2024 in 12 equal monthly installments. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:14 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare option (right to buy) · Derivative | 14,414 | $0.00 Strike: $23.29 | $0.00 |
DisclosureSEC source: 0001209191-23-036263 · doc4.xml · derivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,414 Underlying: Common Shares · 14,414 shares Expires 2033-06-08 F1 · derivative.exercise_date: Options vest over a one-year period commencing June 8, 2023 in 12 equal monthly installments. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 20:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 4,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034383 · doc4.xml · derivative · entry 4 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 2, 2023. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 2, 2023. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 20:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 4,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-034383 · doc4.xml · nonDerivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 4,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034383 · doc4.xml · derivative · entry 3 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,660 Underlying: Common Stock · 4,660 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (Right to Buy) · Derivative | 15,750 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001209191-23-034383 · doc4.xml · derivative · entry 2 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2033-05-31 F2 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 21:21 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 3,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034589 · doc4.xml · derivative · entry 4 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,356 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 3, 2022. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 3, 2022. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 21:21 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 3,356 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-034589 · doc4.xml · nonDerivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 21:21 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 4,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034589 · doc4.xml · derivative · entry 3 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,507 Underlying: Common Stock · 4,507 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 21:21 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (Right to Buy) · Derivative | 15,750 | $0.00 Strike: $14.48 | $0.00 |
DisclosureSEC source: 0001209191-22-034589 · doc4.xml · derivative · entry 2 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2032-06-01 F2 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:06 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare option (right to buy) · Derivative | 16,604 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0000899243-22-020671 · doc4.xml · derivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,604 Underlying: Common Shares · 16,604 shares Expires 2032-05-31 F1 · derivative.exercise_date: Options vest over a one-year period commencing May 31, 2022 in 12 equal monthly installments. Read SEC document |
| June 03, 2021 Filed Jun 5, 2021 00:00 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 3,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038448 · doc4.xml · derivative · entry 2 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,356 Underlying: Common Stock · 3,356 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 03, 2021 Filed Jun 5, 2021 00:00 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (Right to Buy) · Derivative | 12,250 | $0.00 Strike: $21.90 | $0.00 |
DisclosureSEC source: 0001209191-21-038448 · doc4.xml · derivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2031-06-02 F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F2 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:10 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare option (right to buy) · Derivative | 6,120 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0000899243-21-021550 · doc4.xml · derivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,120 Underlying: Common Shares · 6,120 shares Expires 2031-05-28 F1 · derivative.exercise_date: Options vest over a one-year period commencing May 28, 2021 in 12 equal monthly installments. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 22:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionOption Grant (right to buy) · Derivative | 6,632 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-21-007377 · doc4.xml · derivative · entry 4 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,632 shares Expires 2026-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vest in twelve equal monthly installments through June 29, 2017, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 22:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionOption Grant (right to buy) · Derivative | 8,000 | $0.00 Strike: $18.35 | $0.00 |
DisclosureSEC source: 0001209191-21-007377 · doc4.xml · derivative · entry 3 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2028-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option vest in twelve equal monthly installments through June 7, 2019, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 22:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 6,632 | $18.32 | $121,498.24 |
DisclosureSEC source: 0001209191-21-007377 · doc4.xml · nonDerivative · entry 2 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 22:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 8,000 | $18.35 | $146,800.00 |
DisclosureSEC source: 0001209191-21-007377 · doc4.xml · nonDerivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:00 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare Option (right to buy) · Derivative | 8,631 | $0.00 Strike: $16.09 | $0.00 |
DisclosureSEC source: 0001209191-20-040206 · doc4.xml · derivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,631 Underlying: Common Shares · 8,631 shares Expires 2030-06-30 F1 · derivative.exercise_date: Options vest over a one-year period commencing June 30, 2020 in 12 equal monthly installments. Read SEC document |
| June 06, 2020 Filed Jun 8, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 7,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035033 · doc4.xml · derivative · entry 3 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · shares: This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 6, 2020. F4 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 6, 2020. Read SEC document |
| June 06, 2020 Filed Jun 8, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 7,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-035033 · doc4.xml · nonDerivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantOption Grant (right to buy) · Derivative | 16,500 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001209191-20-035033 · doc4.xml · derivative · entry 2 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2030-06-03 F2 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 4, 2020, subject to Reporting Person's continuous service through each such date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 8,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016081 · doc4.xml · derivative · entry 3 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 8,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016081 · doc4.xml · derivative · entry 2 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,876 Underlying: Common Stock · 8,876 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 8,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-016081 · doc4.xml · nonDerivative · entry 1 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:47 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $56.22 | $0.00 |
DisclosureSEC source: 0000899243-19-029440 · doc4.xml · derivative · entry 5 Mehra Anand · CIK 0001590102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2026-05-31 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.